Rethinking Women’s Intimate Health: A Microbiome-First Paradigm Shift
Share
By Dr Smita Salunke, Principal Research Fellow in Pharmaceutics at University College London (UCL), Chief Scientific Officer of EuPFI, and Scientific Advisor to BiotaLife Healthcare

For decades, the clinical management of common vaginal dysbiosis, namely bacterial vaginosis (BV) and vulvovaginal candidiasis (thrush) has relied on anti-infectives and acidifying gels. As a pharmaceutical scientist with over 15 years specializing in formulation design, excipient safety, and global healthcare policy with the WHO and BMGF, I have watched this reactive cycle fail women. Antimicrobials act as blunt instruments: they decimate beneficial Lactobacillus species alongside pathogens, triggering high recurrence rates, secondary yeast overgrowth, and escalating antimicrobial resistance. Meanwhile, traditional acidifying gels frequently cause mucosal irritation and discomfort.
BiotaLife Healthcare is pioneering a new standard of care rooted in formulation science and host-microbiome ecology. Rather than attempting to eradicate microorganisms or artificially force pH, our strategy focuses on restoring natural ecological homeostasis: feeding commensal organisms so they can outcompete pathogens organically.
The Formulation Science Behind Our Pipeline
Our translational research across UCL and King’s College London has led to two distinct, targeted formulations designed for specific clinical and everyday needs:
- DuoBalance™ (Candidate Medical Device): A patented, neutral mucoadhesive hydrogel engineered to treat both BV and thrush without antibiotics, antifungals, or added acidity. Formulated with a precise HPMC-polymer matrix, it delivers a sustained release of glycogen over four hours. Glycogen selectively fuels native Lactobacillus species (L. crispatus, L. gasseri), allowing commensal bacteria to naturally produce lactic acid and hydrogen peroxide. In vitro testing demonstrated a 91% increase in lactobacilli and a 25% reduction in Candida burden within a single dose, as well as significant reductions in pathogen carriage such as Group B Streptococcus (GBS).
- BloomCalma™ (Cosmetic Intimate Care Range): Translating these same pharmaceutical principles into everyday care, BloomCalma is a pH-balanced, fragrance-free moisturising gel formulated to soothe, hydrate, and protect the intimate microbiome. Specially calibrated for high-sensitivity life stages such as pregnancy and postpartum recovery it provides gentle, non-irritating barrier support and hydration without disrupting mucosal microflora.
A Scalable, Evidence-Led Future
Using Quality-by-Design (QbD) principles, our teams at UCL and KCL have optimised these mucoadhesive hydrogel matrices for ideal rheology, shear-thinning spreadability, and patient acceptability, ensuring robust batch-to-batch scalability.

By prioritizing microbiome-first therapies that work with the female anatomy rather than against it, BiotaLife Healthcare is bridging the gap between rigorous academic pharmaceutical science and accessible, life-stage-specific healthcare solutions. It is reshaping bacterial vaginosis treatment by offering more sustainable, preventive and patient-friendly approaches to reducing recurrence and supporting long-term vaginal health.
References
- Tyssen D, Hearps AC, Guntur K, et al. The impact of over-the-counter lactic acid containing vaginal gels on the integrity and inflammatory state of the vaginal epithelium in vitro. Frontiers in Reproductive Health. 2022;4:915948. https://doi.org/10.3389/frph.2022.915948
- Long PF. A new paradigm for treating refractory and recurrent infectious vaginal discharge. JAC-Antimicrobial Resistance. 2025 Jul;7(Suppl 3):dlaf118.017. https://doi.org/10.1093/jacamr/dlaf118.017
FAQ
What is vaginal dysbiosis?
Vaginal dysbiosis is an imbalance in the vaginal microbiome, where protective Lactobacillus bacteria decline and other organisms overgrow. Bacterial vaginosis (BV) and vulvovaginal candidiasis (thrush) are the two most common forms. Dysbiosis can cause symptoms such as unusual discharge, odour, itching and soreness, and it often recurs after treatment.
How do Lactobacillus bacteria protect the vagina?
Lactobacillus species such as L. crispatus and L. gasseri feed on glycogen from the cells lining the vagina and produce lactic acid, which keeps vaginal pH low. Some also produce hydrogen peroxide. This acidic, Lactobacillus-dominated environment makes it harder for the organisms behind BV and thrush to take hold.
Why can antibiotics for BV lead to thrush?
Antibiotics act broadly, so alongside the bacteria behind BV they can also reduce protective Lactobacillus species. With fewer of these bacteria keeping the environment in check, Candida yeast can overgrow, which is why thrush sometimes follows a course of antibiotics. Many women find symptoms switch between BV and thrush over time.
What are excipients, and why does excipient safety matter in intimate care?
Excipients are the ingredients in a product other than the active substance, such as the polymers, preservatives and moisturisers that give a gel its texture and stability. In intimate care they matter because the tissue is delicate: research has shown that some over-the-counter vaginal gels can irritate the vaginal lining because of how concentrated they are.
What is Quality by Design in pharmaceutical formulation?
Quality by Design (QbD) is a systematic approach to developing medicines and medical products. Instead of testing quality in at the end, scientists define the target properties first, such as texture, spreadability and how long a gel stays in place, then design the formulation and manufacturing process to deliver them consistently, batch after batch.
What does a microbiome-first approach mean for BV and thrush?
A microbiome-first approach aims to support the vagina’s own protective bacteria rather than trying to eradicate microorganisms or force pH down with acids. BiotaLife’s DuoBalance candidate medical device is designed to feed native Lactobacillus species with glycogen. It is now advancing into clinical trials and is not yet available to buy.
Who is Dr Smita Salunke?
Dr Smita Salunke is Principal Research Fellow in Pharmaceutics at University College London (UCL), Chief Scientific Officer of the European Paediatric Formulation Initiative (EuPFI) and Scientific Advisor to BiotaLife Healthcare. She has more than 15 years of experience in formulation design, excipient safety and global healthcare policy, including work with the WHO and the Bill & Melinda Gates Foundation.